Evaluation of efficacy and safety of CQ Extract in obese subjects – A Randomized, Double Blind, Multicenter, Placebo Controlled, Comparative, Interventional, Prospective, Clinical Study - NIL

Start Date08 Jan 2024

Sponsor / Collaborator

Nisarga Biotech Pvt Ltd.

CTRI/2023/10/058565 / CompletedNot Applicable

A study to determine comparative bioavailability of NCT023 extracts Vs Curcuma longa extract with Piperine in healthy volunteers. - NIL

Start Date23 Oct 2023

Sponsor / Collaborator

Nisarga Biotech Pvt Ltd.

CTRI/2023/09/057801 / Not yet recruitingPhase 2

Clinical validation of the potential of herbal extract blend in alleviating the stress and related conditions: A randomized, placebo-controlled, cross-over clinical study. - Nil

Start Date28 Sep 2023

Sponsor / Collaborator

Nisarga Biotech Pvt Ltd.

100 Clinical Results associated with Nisarga Biotech Pvt Ltd.

0 Patents (Medical) associated with Nisarga Biotech Pvt Ltd.

Literatures (Medical) associated with Nisarga Biotech Pvt Ltd.

01 Oct 2021·Journal of Ayurveda and Integrative Medicine

In vitro and in vivo evaluation of a standardized Curcuma longa Linn formulation in cervical cancer

Article

Author: Amonkar, A J ; Paradkar, P H ; Soman, G ; Barkume, M S ; Juvekar, A S ; Vaidya, A D B ; Joshi, J V

BACKGROUNDThe anti-cancer activity of phytomolecules present in turmeric or haridra (Curcuma longa Linn) extracts against cancer has been described in various 'in vitro and in vivo' studies.OBJECTIVEIn the present study, in vitro and in vivo anti-cancer and chemo-preventive activity of a new standardized Supercritical Turmeric Oil Extract (SCTOE) NBFR-03 was evaluated in cervical cancer models.METHODS AND MATERIALSIn vitro cytotoxicity of this formulation was assessed at 10, 20, 40, and 80 μg/ml concentrations, in three cervical cancer cell lines (HeLa, SiHa, ME180) using Sulforhodamine B assay. The in vivo anti-cancer activity was evaluated in two groups of female nude mice; the first one was with tumor xenograft implants and at the same time treatment was started with 96 μl/kg/day p.o. and 192 μl/kg/day p.o. NBFR-03 for three months. The second group was kept as chemoprevention group where mice were pre-treated with the formulation (96 μl/kg/day p.o.) for two weeks and injected with cancer cell suspension with continued treatment for three months.RESULTSNo cytotoxicity was seen in any cell line with the extract when compared to positive control (Adriamycin 10 μg/ml). In mice the first treatment group with tumor xenograft implants did not show any significant anti-tumor activity but showed a trend where higher dose group had smaller tumor volumes as compared to lower dose group and controls (p = 0.37 and p = 0.34 respectively). The chemopreventive group with pre-treated mice also showed smaller tumor size as compared to controls (p = 0.163).CONCLUSIONNBFR-03 turmeric oil extract showed a promising trend in mice pre-treated with NBFR-03. There is a scope for further studying the potential of this extract as complementary therapy and as a chemopreventive.

01 Jan 2021·Methods in Molecular Biology

Improved Immunoprecipitation to Mass Spectrometry Method for the Enrichment of Low-Abundant Protein Targets

Article

Author: Patel, Bhavin ; Kaboord, Barbara ; Smith, Suzanne ; Sabnis, Renuka ; Jensen, Penny

Immunoprecipitation (IP) is commonly used upstream of mass spectrometry (MS) as an enrichment tool for low-abundant protein targets. However, several aspects of the classical IP procedure such as nonspecific protein binding to the isolation matrix, detergents or high salt concentrations in wash and elution buffers, and antibody chain contamination in elution fractions render it incompatible with downstream mass spectrometry analysis. Here, we discuss an improved IP-MS workflow that is designed to minimize sample prep time and these contaminants. The method employs biotinylated antibodies to the targets of interest and streptavidin magnetic beads that exhibit low background binding. In addition, alterations in the elution protocol and subsequent MS sample prep were made to reduce time and antibody leaching in the eluent, minimizing potential ion suppression effects and thereby maximizing detection of multiple target antigens and interacting proteins.

21 Feb 2019·AgingQ3 · MEDICINE

Nutraceutical effects of Emblica officinalis in age-related macular degeneration

Q3 · MEDICINE

Article

Author: Kuppermann, Baruch D. ; Nesburn, Anthony B. ; Kanodia, Raj ; Soman, Girish ; Nashine, Sonali ; Kenney, M. Cristina

Emblicaofficinalis Gaetrn (i.e., Phyllanthus emblica/ Indian gooseberry/ Amla) (EO) has been used extensively as a nutraceutical in several diseases since it is known to boost immunity and offers numerous health benefits such as antioxidant, anti-inflammatory, and anti-aging effects. The goal of our study was to test the hypothesis that EO will rescue human AMD RPE transmitochondrial cells from mitochondria-induced cellular damage. AMD RPE transmitochondrial cell lines were created by fusion of mitochondria DNA-deficient APRE-19 (Rho0) cells with platelets isolated from AMD patients, and therefore had identical nuclei but differed in mitochondrial DNA content. These AMD RPE cells were treated with EO extract followed by characterization of effects of EO using cellular and molecular assays. Herein, EO significantly improved live cell number and mitochondrial membrane potential, reduced apoptosis and oxidative stress, down-regulated VEGF, and up-regulated PGC-1α. In conclusion, EO improved cellular and mitochondrial health, thereby playing a key cytoprotective role in AMD in vitro. Further studies are required to examine the mechanisms that mediate the cytoprotective effects of EO.

100 Deals associated with Nisarga Biotech Pvt Ltd.

100 Translational Medicine associated with Nisarga Biotech Pvt Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nisarga Biotech Pvt Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing